Skip to content

Advertisement

Open Peer Review Reports for: PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
2 Jul 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
27 Aug 2012 Reviewed Reviewer Report - William Schelman
4 Sep 2012 Reviewed Reviewer Report - James Cleary
4 Sep 2012 Reviewed Reviewer Report - Wan-Teck Lim
3 Oct 2012 Author responded Author comments - Mark McKeage
Resubmission - Version 3
3 Oct 2012 Submitted Manuscript version 3
18 Oct 2012 Author responded Author comments - Mark McKeage
Resubmission - Version 4
18 Oct 2012 Submitted Manuscript version 4
Publishing
23 Oct 2012 Editorially accepted
25 Oct 2012 Article published 10.1186/1471-2407-12-496

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement